Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases

Melanoma Research

Volumn 26, Issue 4, 2016, Pages 382-386

  Patel, Bindiya G ^a   Ahmed, Kamran A ^b   Johnstone, Peter A S ^b   Yu, Hsiang Hsuan Michael ^b   Etame, Arnold B ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

BRAF inhibitor; brain metastasis; MEK inhibitor; melanoma; stereotactic radiosurgery

Indexed keywords

DABRAFENIB; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; TRAMETINIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; ENZYME INHIBITION; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MALE; MEDICAL RECORD REVIEW; MELANOMA; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME; AGED; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CHEMORADIOTHERAPY; PATHOLOGY; PROCEDURES; RADIOSURGERY; SECONDARY; SKIN TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; HUMANS; IMIDAZOLES; MALE; MAP KINASE KINASE 1; MELANOMA; MIDDLE AGED; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; RADIOSURGERY; SKIN NEOPLASMS;

EID: 84959295575     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000250     Document Type: Article

References (27)

1. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102:1213-1218.
2. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30:419-425.
3. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-2147.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
5. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-714.
6. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:1087-1095.
7. Chapman PB. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation. Am Soc Clin Oncol Educ Book 2013. [Epub ahead of print].
8. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694-1703.
9. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386:444-451.
10. Gaudy-Marqueste C, Carron R, Delsanti C, Loundou A, Monestier S, Archier E, et al. On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. Ann Oncol 2014; 25:2086-2091.
11. Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 2015; 122:121-126.
12. Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, et al. Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 2013; 113:411-416.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
14. Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 2014; 50:611-621.
15. Zhang W. BRAF inhibitors: the current and the future. Curr Opin Pharmacol 2015; 23:68-73.
16. Ramakrishna N, Margolin KA. Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am Soc Clin Oncol Educ Book 2013. 399-403.
17. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-330.
18. Boussemart L, Boivin C, Claveau J, Tao YG, Tomasic G, Routier E, et al. Vemurafenib and radiosensitization. JAMA Dermatol 2013; 149:855-857.
19. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
20. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
21. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30-39.
22. Chang EL, Selek U, Hassenbusch SJ 3rd, Maor MH, Allen PK, Mahajan A, et al. Outcome variation among 'radioresistant' brain metastases treated with stereotactic radiosurgery. Neurosurgery 2005; 56:936-945. discussion 936-945.
23. Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011; 6:48.
24. Sambade MJ, Peters EC, Thomas NE, Kaufmann WK, Kimple RJ, Shields JM. Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. Radiother Oncol 2011; 98:394-399.
25. Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013; 31:e283-e287.
26. Schulze B, Meissner M, Wolter M, Rödel C, Weiss C. Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. Strahlenther Onkol 2014; 190:229-232.
27. Harding JJ, Barker CA, Carvajal RD, Wolchok JD, Chapman PB, Lacouture ME. Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol 2014; 32:e54-e56.